Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Bertoni

Showing results (121-130 of 325) with videos related to

Pageof 33
Sort By:
Human Pathology|July 16, 2008
Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomasDaniela Furlan, Nora Sahnane, Ileana Carnevali, et al.
BMC Bioinformatics|October 28, 2018
cuRnet: an R package for graph traversing on GPUVincenzo Bonnici, Federico Busato, Stefano Aldegheri, et al.
Neoplasia (New York, N.Y.)|October 13, 2006
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cellsSara Vignati, Veronica Albertini, Andrea Rinaldi, et al.
Journal of Clinical Medicine|January 21, 2023
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK InhibitorsFrancesca Guidetti, Alberto J Arribas, Giulio Sartori, et al.
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
Leukemia Research|April 10, 2010
Syk expression patterns differ among B-cell lymphomasMaurilio Ponzoni, Silvia Uccella, Michael Mian, et al.
Leukemia Research|March 23, 2011
Chromosome 11q23.1 is an unstable region in B-cell tumor cell linesGiulia Poretti, Ivo Kwee, Barbara Bernasconi, et al.
Molecular Cancer|December 12, 2022
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signalingCeleste Rizzello, Valeria Cancila, Sabina Sangaletti, et al.
Veterinary Pathology|March 23, 2023
Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signatureLuca Licenziato, Lucia Minoli, Ugo Ala, et al.
Oncotarget|February 12, 2015
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseAfua Adjeiwaa Mensah, Ivo Kwee, Eugenio Gaudio, et al.
Pageof 33

Showing results (121-130 of 325) with videos related to

Sort By:
Pageof 33
Human Pathology|July 16, 2008
Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomasDaniela Furlan, Nora Sahnane, Ileana Carnevali, et al.
BMC Bioinformatics|October 28, 2018
cuRnet: an R package for graph traversing on GPUVincenzo Bonnici, Federico Busato, Stefano Aldegheri, et al.
Neoplasia (New York, N.Y.)|October 13, 2006
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cellsSara Vignati, Veronica Albertini, Andrea Rinaldi, et al.
Journal of Clinical Medicine|January 21, 2023
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK InhibitorsFrancesca Guidetti, Alberto J Arribas, Giulio Sartori, et al.
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
Leukemia Research|April 10, 2010
Syk expression patterns differ among B-cell lymphomasMaurilio Ponzoni, Silvia Uccella, Michael Mian, et al.
Leukemia Research|March 23, 2011
Chromosome 11q23.1 is an unstable region in B-cell tumor cell linesGiulia Poretti, Ivo Kwee, Barbara Bernasconi, et al.
Molecular Cancer|December 12, 2022
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signalingCeleste Rizzello, Valeria Cancila, Sabina Sangaletti, et al.
Veterinary Pathology|March 23, 2023
Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signatureLuca Licenziato, Lucia Minoli, Ugo Ala, et al.
Oncotarget|February 12, 2015
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseAfua Adjeiwaa Mensah, Ivo Kwee, Eugenio Gaudio, et al.
Pageof 33